California’s Cowardly Politicians Gut Psychedelic Decriminalization Bill
The California legislature had the power to act on psychedelic decriminalization, but instead decided to continue the War on Drugs
Entries by James Hallifax
MindMed Shelves 18-MC for Opioid Use Disorder and Further Cuts Pipeline
MindMed drops its proprietary ibogaine for opioid addiction research amidst an ongoing shakeup. What is going on with this psychedelics company?
An Inside Look into Field Trip’s Next-Generation Psychedelic, FT-104
Field Trip is the only company exploring the therapeutic potential of a 4-HO-DiPT prodrug called FT-104. But how does it work?
Compass Pathways Sued for Stealing Trade Secrets
Compass Pathways faces a legal challenge from Terran Biosciences over the potential theft of intellectual property
Three Phase 3 Clinical Trials that Could Legalize Psychedelics
The road to psychedelic legalization has many paths. These 3 clinical trials have the best chances to legalize psychedelics for therapy
The Top 5 Psychedelics Podcasts
New psychedelic podcasts are popping up every week, but which ones are worth listening to? Here's a few of our favorites.
The Real Reason Cybin Bought Entheon’s DMT Clinical Trial
In a rare move Cybin aquires a phase 1 DMT clinical trial from Entheon Biomedical. CEO Doug Drysdale explains why in a Reddit AMA
The DEA Backs Down, Will Not Criminalize 5 Psychedelics
This week the DEA announced it would withdraw its plan to schedule 5 research psychedelics. But we shouldn't celebrate just yet
3 Microdosing Clinical Trials to Keep an Eye On
Does microdosing psychedelics work, or is it the placebo effect? Here are 3 microdosing clinical trials looking for answers
A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial
Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research
